There is an expanding role for molecular biomarker tests to aid treatment decisions and prognostication such as IDH1/2 mutation, MGMT promoter methylation, 1p19q co-deletion, pTERT (C228T, C250T), H3.3 (K27M and G34R/V), as well as Next Generation Sequencing Glioma Panel using these tumour tissue samples. This evidence concerns the gene IDH1 and glioma.